Balance Sheet
Cash Flow Statement
Net Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Long-Term Debt Repayments (2019 - 2024)

Historic Long-Term Debt Repayments for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to -$9.5 million.

  • Innate Pharma's Long-Term Debt Repayments fell 27590.01% to -$9.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$13.8 million, marking a year-over-year decrease of 8770.46%. This contributed to the annual value of -$9.5 million for FY2024, which is 27590.01% down from last year.
  • According to the latest figures from Q4 2024, Innate Pharma's Long-Term Debt Repayments is -$9.5 million, which was down 27590.01% from -$2.5 million recorded in Q4 2023.
  • Over the past 5 years, Innate Pharma's Long-Term Debt Repayments peaked at -$1.0 million during Q2 2022, and registered a low of -$9.5 million during Q4 2024.
  • For the 5-year period, Innate Pharma's Long-Term Debt Repayments averaged around -$2.7 million, with its median value being -$2.1 million (2022).
  • As far as peak fluctuations go, Innate Pharma's Long-Term Debt Repayments skyrocketed by 2468.1% in 2022, and later crashed by 27590.01% in 2024.
  • Innate Pharma's Long-Term Debt Repayments (Quarter) stood at -$2.7 million in 2020, then rose by 11.57% to -$2.4 million in 2021, then rose by 12.67% to -$2.1 million in 2022, then dropped by 22.9% to -$2.5 million in 2023, then crashed by 275.9% to -$9.5 million in 2024.
  • Its last three reported values are -$9.5 million in Q4 2024, -$2.5 million for Q4 2023, and -$1.7 million during Q2 2023.